<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02590510</url>
  </required_header>
  <id_info>
    <org_study_id>BH 001</org_study_id>
    <nct_id>NCT02590510</nct_id>
  </id_info>
  <brief_title>Different Dose of Methotrexate for the Treatment of Meningeal Carcinomatosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hui Bu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Medical University</source>
  <brief_summary>
    <textblock>
      The main purpose of this study is to compare the effect of 10 mg and 15 mg methotrexate in
      the treatment of meningeal carcinomatosis.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2015</start_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of adverse reactions</measure>
    <time_frame>one year</time_frame>
    <description>In accordance with the standard of CTCAE, an assessment will be assessed every month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KPS score</measure>
    <time_frame>one year</time_frame>
    <description>In accordance with the standard of KPS(Karnofsky Performance Status,KPS) score, an assessment will be assessed every month</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Meningeal Carcinomatosis</condition>
  <arm_group>
    <arm_group_label>The small dose of group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose of methotrexate is 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The high dose of group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The dose of methotrexate is 15 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <description>The quantity of methotrexate is different in the two groups.</description>
    <arm_group_label>The small dose of group</arm_group_label>
    <arm_group_label>The high dose of group</arm_group_label>
    <other_name>Intrathecal chemotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 14 or more

          -  a history of solid tumor

          -  a new clinical neurological signs and symptoms

          -  a typical CT(Computerized Tomography,CT) or MRI(Magnetic Resonance Imaging,MRI)
             imaging findings

          -  tumor cells in cerebrospinal fluid

        Exclusion Criteria:

          -  KPS score &lt;60

          -  the tumor patients with organ failure

          -  bacteria, fungi or viral meningitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Second Hospital of Hebei Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hui Bu</last_name>
    <phone>86-13831106903</phone>
    <email>buhuimy1@163.com</email>
  </overall_contact>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2015</study_first_submitted>
  <study_first_submitted_qc>October 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2015</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University</investigator_affiliation>
    <investigator_full_name>Hui Bu</investigator_full_name>
    <investigator_title>Study Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Intrathecal chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Meningeal Carcinomatosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

